



Novelix Pharmaceuticals limited

(Formerly TRIMURTHI LIMITED) CIN: L67120TG1994PLC018956
(NOVELIX | 536565 | INE314I01036)

Date: 19th January, 2026

To,
The Deputy Manager
Department of Corporate Services
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai-400001.

Sub : Outcome of Board Meeting held on Monday, 19th January, 2026.

Ref: Scrip Code: 536565
Scrip Id: NOVELIX

Respected Sir/Madam,

This is to inform that Board of Directors of the Company in its meeting held on **19th January, 2026** at the Registered office of the company i.e., H No: 3-6-237/610, Flat No: 610, 6Th Floor, Lingapur LA Builders, Also Known as Amrutha Estates, Himayat Nagar, Hyderabad, Telangana- 500029, which commenced at 5:00 P.M. has considered and approved:

1. The allotment of 400,000 equity shares of the face value of Rs. 10 each at an issue price of Rs. 20/- each (including a premium of Rs. 10/- per share), fully paid-up upon exercising the option available with warrant holders (person belonging to non promoter category who have paid Rs. 15/- per warrant i.e. the remaining 75% of issue price) to convert 400,000 warrants out of 15,000,000 warrants (Already Converted (7265000) allotted on 10th January, 2025 on preferential basis through Special resolution passed by the shareholders of the Company at the Extra-Ordinary General Meeting on November 18th 2024 and In-Principle approval received from the BSE Limited on December 31st 2024.
2. Considered and approved the appointment of Mr. Gnana Prakash Gattu (DIN: 00517921) Director of the Company as Nodal Officer under the Investor Education and Protection Fund Authority (Accounting, Audit, Transfer and Refund) Rules, 2016 (the “IEPF Rules”)

Details as required as per Regulation 30 of SEBI (LODR) Regulations, 2015 read with SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 09, 2015 and SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 is attached herewith as annexure I.

The Meeting was concluded at 05:30 P.M. with the vote of thanks.

We request you to take the aforesaid information on record for dissemination through your website.

Thanking you
Yours sincerely,

For Novelix Pharmaceuticals Limited



Venkateshwarlu Pulluru
(Whole-time director)
DIN: 02076871

Novelix Pharmaceuticals limited

(Formerly Known as TRIMURTHI LIMITED)

H No: 3-6-237/610, Flat No: 610, 6th Floor, Lingapur LA Builders, Also Known as Amrutha Estates, Himayat Nagar, Hyderabad, Telangana- 500029 Ph No: +91 8977631044 Email: novelixpharmaceuticals@gmail.com
www.novelixpharma.com



Annexure I

Details as required as per Regulation 30 of SEBI (LODR) Regulations, 2015 read with Circular No. CIR/CFD/CMD/4/2015 dated September 09, 2015 and SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024:

- Type of securities proposed to be issued-** Equity Shares upon conversion of Warrants.
- Type of Issuance-** Preferential issue to Promoter & Non promoters.
- Total Number of Equity Shares Allotted:** 400,000 Equity Shares issued upon conversion of equal number of Warrants (face value of Rs. 10/-) @ Rs. 20 each.
- Names of the allottees of Equity Shares:**

| Sr. No. | Name of the Allottees | No. of Equity Shares allotted |
|---|-----------------------|-------------------------------|
| Strategic Investors (Non- Promoters) | | |
| 1. | Arpan Vipin Mantri | 200,000 |
| 2. | Yellaboina Dhanraj | 150,000 |
| 3. | Sudhir Kumar Agarwal | 50,000 |

5. Post Allotment of Equity Shares:

- Outcome of Subscription-** The Company has received Rs. 60,00,000.00/- (Rupees Sixty Lakhs) (75% of issue price) on allotment of 400,000 (Four Lakhs) Equity Shares upon conversion of 400000 warrants out of 1,50,00,000 warrants allotted on 10th January, 2025. (*Issue price of Rs. 20/- per equity share*)
- Issue Price/ Allotted Price-** Issue price of Rs. 20/- each (Face Value Rs. 10/- each + Premium Rs. 10/- each)
- Number of Investors- 3**

Consequent to the aforesaid allotment of 400000 (Four Lakhs) Equity Shares; the paid-up equity capital of the Company has increased from Rs. 172,150,000.00/- consisting of 1,72,15,000 Equity Shares of Rs. 10/- each to Rs. 176,150,000.00/- consisting of 1,76,15,000 Equity Shares of Rs. 10/- each.

6. In case of convertibles-Intimation on conversion of securities or on lapse of the tenure of the instrument: Intimation on conversion of securities.

Venuhul
